{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:37:26Z","timestamp":1776659846778,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["SPF202309017513"],"award-info":[{"award-number":["SPF202309017513"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009411","name":"Universit\u00e9 Paris-Est Cr\u00e9teil","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Huntington\u2019s disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. Many studies attempt, besides age and CAG, to understand the factors that impact disease progression. Biological tests measuring several metabolic and inflammatory factors are frequently performed in outpatients, but their relation with disease progression is unknown. This study aims to evaluate the association between routine biological profiles at the early manifest stage of HD and subsequent disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2936 participants, the SPOT-HD database (combination of French part of REGISTRY, BIO-HD and REPAIR-HD), we selected 227 HD mutation carriers at an early stage of HD (HD-ISS stage 2 and CAP\u2009&lt;\u2009150), having both longitudinal measurements of routine blood biomarkers and clinical progression assessed using the Unified Huntington\u2019s Disease Rating Scale. Identification of biological routine profiles was performed using an iterative non-parametric model selection with dimensionality reduction algorithm, k-means clustering, LASSO regression, and Random Forest. Disease progression of each profile was estimated using generalized additive modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three profiles were identified with distinct trajectories of HD progression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The Rapid-Progression Profile with relatively higher levels of triglycerides, liver enzymes, and body mass index, coupled with lower high-density lipoprotein (HDL) cholesterol levels was noted. The Intermediate-Progression profile with relatively higher HDL levels, lower triglycerides, and inflammatory and liver markers in the lower end of the normal range was noticed. The Slow-Progression Profile with a tendency for higher T4 and creatinine levels, a greater concentration of lymphocytes than in other profiles, and low HDL despite normal triglycerides were studied.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biological routine profiles may help anticipating HD progression, thus facilitating personalized medicine approaches. These findings suggest that routine metabolic and inflammatory markers may be useful for patient follow-up in HD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13717-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:59:31Z","timestamp":1775152771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Profiles of patients at early stages of Huntington\u2019s disease based on the routine biological markers and the disease progression"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7838-8752","authenticated-orcid":false,"given":"Andres","family":"Gil-salcedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Massart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Youssov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u00e7a","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Catherine","family":"Bachoud-Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"1","key":"13717_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ (2018) Huntington\u2019s disease: a clinical review. Eur J Neurol 25(1):24\u201334","journal-title":"Eur J Neurol"},{"issue":"2","key":"13717_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biology14020129","volume":"14","author":"S Aqel","year":"2025","unstructured":"Aqel S, Ahmad J, Saleh I et al (2025) Advances in Huntington\u2019s disease biomarkers: a 10-year bibliometric analysis and a comprehensive review. Biology 14(2):129","journal-title":"Biology"},{"key":"13717_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.650278","volume":"8","author":"Z Li","year":"2021","unstructured":"Li Z, Zhao H, Wang J (2021) Metabolism and chronic inflammation: the links between chronic heart failure and comorbidities. Front Cardiovasc Med 8:650278","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"13717_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/0271678X221135061","volume":"43","author":"TS McDonald","year":"2023","unstructured":"McDonald TS, Lerskiatiphanich T, Woodruff TM, McCombe PA, Lee JD (2023) Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders. J Cereb Blood Flow Metab 43(1):26\u201343","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"13717_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41467-022-35752-x","volume":"14","author":"A Matsushima","year":"2023","unstructured":"Matsushima A, Pineda SS, Crittenden JR et al (2023) Transcriptional vulnerabilities of striatal neurons in human and rodent models of Huntington\u2019s disease. Nat Commun 14(1):282","journal-title":"Nat Commun"},{"issue":"2","key":"13717_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/01677068409107083","volume":"1","author":"SE Folstein","year":"1984","unstructured":"Folstein SE, Abbott MH, Franz ML, Huang S, Chase GA, Folstein MF (1984) Phenotypic heterogeneity in Huntington\u2019s disease. J Neurogenet 1(2):175\u2013184","journal-title":"J Neurogenet"},{"issue":"1","key":"13717_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/br.2022.1587","volume":"18","author":"AM Palaiogeorgou","year":"2023","unstructured":"Palaiogeorgou AM, Papakonstantinou E, Golfinopoulou R et al (2023) Recent approaches on Huntington\u2019s disease (review). Biomed Rep 18(1):5","journal-title":"Biomed Rep"},{"key":"13717_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc2888","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues FB, Byrne LM, Tortelli R et al (2020) Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abc2888","journal-title":"Sci Transl Med"},{"issue":"8","key":"13717_CR9","doi-asserted-by":"publisher","first-page":"e717","DOI":"10.1212\/WNL.0000000000005005","volume":"90","author":"EB Johnson","year":"2018","unstructured":"Johnson EB, Byrne LM, Gregory S et al (2018) Neurofilament light protein in blood predicts regional atrophy in Huntington\u2019s disease. Neurology 90(8):e717\u2013e723","journal-title":"Neurology"},{"key":"13717_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104710","volume":"94","author":"C Sampaio","year":"2023","unstructured":"Sampaio C, Wilkinson HA (2023) Facilitating Huntington\u2019s disease research: plasma neurofilament levels as a promising enrichment biomarker for HD-ISS stage 1. EBioMedicine 94:104710","journal-title":"EBioMedicine"},{"issue":"1","key":"13717_CR11","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1038\/s41598-023-32630-4","volume":"13","author":"S Vauleon","year":"2023","unstructured":"Vauleon S, Schutz K, Massonnet B et al (2023) Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies. Sci Rep 13(1):5332","journal-title":"Sci Rep"},{"issue":"6","key":"13717_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac309","volume":"4","author":"NS Caron","year":"2022","unstructured":"Caron NS, Haqqani AS, Sandhu A et al (2022) Cerebrospinal fluid biomarkers for assessing Huntington\u2019s disease onset and severity. Brain Commun 4(6):fcac309","journal-title":"Brain Commun"},{"key":"13717_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105411","author":"S Marti-Martinez","year":"2022","unstructured":"Marti-Martinez S, Valor LM (2022) A glimpse of molecular biomarkers in Huntington\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23105411","journal-title":"Int J Mol Sci"},{"issue":"5","key":"13717_CR14","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00415-023-11572-x","volume":"270","author":"S Zhang","year":"2023","unstructured":"Zhang S, Cheng Y, Shang H (2023) The updated development of blood-based biomarkers for Huntington\u2019s disease. J Neurol 270(5):2483\u20132503","journal-title":"J Neurol"},{"key":"13717_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030385","author":"KH Chang","year":"2023","unstructured":"Chang KH, Cheng ML, Lo CJ, Fan CM, Wu YR, Chen CM (2023) Alternations of lipoprotein profiles in the plasma as biomarkers of Huntington\u2019s disease. Cells. https:\/\/doi.org\/10.3390\/cells12030385","journal-title":"Cells"},{"issue":"1","key":"13717_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacl.2009.11.003","volume":"4","author":"RC Block","year":"2010","unstructured":"Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I (2010) Altered cholesterol and fatty acid metabolism in Huntington\u2019s disease. J Clin Lipidol 4(1):17\u201323","journal-title":"J Clin Lipidol"},{"key":"13717_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15010010","author":"A Yilmaz","year":"2025","unstructured":"Yilmaz A, Akyol S, Ashrafi N, Saiyed N, Turkoglu O, Graham SF (2025) Lipidomics of Huntington\u2019s disease: a comprehensive review of current status and future directions. Metabolites. https:\/\/doi.org\/10.3390\/metabo15010010","journal-title":"Metabolites"},{"issue":"43","key":"13717_CR18","doi-asserted-by":"publisher","first-page":"9932","DOI":"10.1523\/JNEUROSCI.3355-05.2005","volume":"25","author":"M Valenza","year":"2005","unstructured":"Valenza M, Rigamonti D, Goffredo D et al (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington\u2019s disease. J Neurosci 25(43):9932\u20139939","journal-title":"J Neurosci"},{"key":"13717_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.797220","volume":"14","author":"R Kacher","year":"2022","unstructured":"Kacher R, Mounier C, Caboche J, Betuing S (2022) Altered cholesterol homeostasis in Huntington\u2019s disease. Front Aging Neurosci 14:797220","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"13717_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146480","volume":"11","author":"R Nambron","year":"2016","unstructured":"Nambron R, Silajdzic E, Kalliolia E et al (2016) A metabolic study of Huntington\u2019s disease. PLoS ONE 11(1):e0146480","journal-title":"PLoS ONE"},{"issue":"7","key":"13717_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Schobel S, Gantman EC et al (2022) A biological classification of Huntington\u2019s disease: the integrated staging system. Lancet Neurol 21(7):632\u2013644","journal-title":"Lancet Neurol"},{"issue":"3","key":"13717_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JHD-170253","volume":"6","author":"MT Montojo","year":"2017","unstructured":"Montojo MT, Aganzo M, Gonzalez N (2017) Huntington\u2019s disease and diabetes: chronological sequence of its association. J Huntingtons Dis 6(3):179\u2013188","journal-title":"J Huntingtons Dis"},{"key":"13717_CR23","doi-asserted-by":"publisher","first-page":"20681","DOI":"10.1038\/srep20681","volume":"6","author":"RR Handley","year":"2016","unstructured":"Handley RR, Reid SJ, Patassini S et al (2016) Metabolic disruption identified in the Huntington\u2019s disease transgenic sheep model. Sci Rep 6:20681","journal-title":"Sci Rep"},{"issue":"5","key":"13717_CR24","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1073\/pnas.0536856100","volume":"100","author":"W Duan","year":"2003","unstructured":"Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 100(5):2911\u20132916","journal-title":"Proc Natl Acad Sci USA"},{"key":"13717_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1374365","volume":"15","author":"JQ Xia","year":"2024","unstructured":"Xia JQ, Cheng YF, Zhang SR et al (2024) The characteristic and prognostic role of blood inflammatory markers in patients with Huntington\u2019s disease from China. Front Neurol 15:1374365","journal-title":"Front Neurol"},{"issue":"Pt 3","key":"13717_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Trager","year":"2014","unstructured":"Trager U, Andre R, Lahiri N et al (2014) HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain 137(Pt 3):819\u2013833","journal-title":"Brain"},{"key":"13717_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8653132","volume":"2016","author":"NP Rocha","year":"2016","unstructured":"Rocha NP, Ribeiro FM, Furr-Stimming E, Teixeira AL (2016) Neuroimmunology of Huntington\u2019s disease: revisiting evidence from human studies. Mediators Inflamm 2016:8653132","journal-title":"Mediators Inflamm"},{"issue":"6","key":"13717_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.25862","volume":"29","author":"R Hoffmann","year":"2014","unstructured":"Hoffmann R, Stuwe SH, Goetze O et al (2014) Progressive hepatic mitochondrial dysfunction in premanifest Huntington\u2019s disease. Mov Disord 29(6):831\u2013834","journal-title":"Mov Disord"},{"key":"13717_CR29","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302098","author":"RM Bragg","year":"2023","unstructured":"Bragg RM, Coffey SR, Cantle JP et al (2023) Huntingtin loss in hepatocytes is associated with altered metabolism, adhesion, and liver zonation. Life Sci Alliance. https:\/\/doi.org\/10.26508\/lsa.202302098","journal-title":"Life Sci Alliance"},{"issue":"12","key":"13717_CR30","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1084\/jem.20160776","volume":"213","author":"MH Disatnik","year":"2016","unstructured":"Disatnik MH, Joshi AU, Saw NL et al (2016) Potential biomarkers to follow the progression and treatment response of Huntington\u2019s disease. J Exp Med 213(12):2655\u20132669","journal-title":"J Exp Med"},{"issue":"1","key":"13717_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3233\/JHD-220555","volume":"12","author":"JD Long","year":"2023","unstructured":"Long JD, Gantman EC, Mills JA et al (2023) Applying the Huntington\u2019s disease integrated staging system (HD-ISS) to observational studies. J Huntingtons Dis 12(1):57\u201369","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"13717_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JHD-210475","volume":"11","author":"JH Warner","year":"2022","unstructured":"Warner JH, Long JD, Mills JA et al (2022) Standardizing the CAP score in Huntington\u2019s disease by predicting age-at-onset. J Huntingtons Dis 11(2):153\u2013171","journal-title":"J Huntingtons Dis"},{"issue":"15_supplement","key":"13717_CR33","doi-asserted-by":"publisher","first-page":"1.8","DOI":"10.1212\/WNL.92.15_supplement.P1.8-043","volume":"92","author":"D Trundell","year":"2019","unstructured":"Trundell D, Palermo G, Schobel S, Long JD, Leavitt BR, Tabrizi SJ (2019) Defining clinically meaningful change on the Composite Unified Huntington\u2019s Disease Rating Scale (cUHDRS) (P1.8\u2013043). Neurology 92(15_supplement):1.8-043","journal-title":"Neurology"},{"issue":"6","key":"13717_CR34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/sim.4780100609","volume":"10","author":"P Bauer","year":"1991","unstructured":"Bauer P (1991) Multiple testing in clinical trials. Stat Med 10(6):871\u2013889 (discussion 89\u201390)","journal-title":"Stat Med"},{"issue":"1","key":"13717_CR35","doi-asserted-by":"publisher","first-page":"20314","DOI":"10.1038\/s41598-020-76973-8","volume":"10","author":"GR Phillips","year":"2020","unstructured":"Phillips GR, Hancock SE, Brown SHJ et al (2020) Cholesteryl ester levels are elevated in the caudate and putamen of Huntington\u2019s disease patients. Sci Rep 10(1):20314","journal-title":"Sci Rep"},{"key":"13717_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jns.2016.02.018","volume":"362","author":"SM Nielsen","year":"2016","unstructured":"Nielsen SM, Vinther-Jensen T, Nielsen JE et al (2016) Liver function in Huntington\u2019s disease assessed by blood biochemical analyses in a clinical setting. J Neurol Sci 362:326\u2013332","journal-title":"J Neurol Sci"},{"key":"13717_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00103","volume":"13","author":"TA Intihar","year":"2019","unstructured":"Intihar TA, Martinez EA, Gomez-Pastor R (2019) Mitochondrial dysfunction in Huntington\u2019s disease; interplay between HSF1, p53 and PGC-1alpha transcription factors. Front Cell Neurosci 13:103","journal-title":"Front Cell Neurosci"},{"issue":"3\u20134","key":"13717_CR38","first-page":"223","volume":"18","author":"NA Aziz","year":"2007","unstructured":"Aziz NA, Swaab DF, Pijl H, Roos RA (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington\u2019s disease: clinical consequences and therapeutic implications. Rev Neurosci 18(3\u20134):223\u2013251","journal-title":"Rev Neurosci"},{"issue":"3","key":"13717_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004962","volume":"4","author":"N Saleh","year":"2009","unstructured":"Saleh N, Moutereau S, Durr A et al (2009) Neuroendocrine disturbances in Huntington\u2019s disease. PLoS ONE 4(3):e4962","journal-title":"PLoS ONE"},{"key":"13717_CR40","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab112","author":"J Zhou","year":"2021","unstructured":"Zhou J, Gauthier K, Ho JP et al (2021) Thyroid hormone receptor alpha regulates autophagy, mitochondrial biogenesis, and fatty acid use in skeletal muscle. Endocrinology. https:\/\/doi.org\/10.1210\/endocr\/bqab112","journal-title":"Endocrinology"},{"issue":"3","key":"13717_CR41","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1080\/15548627.2020.1728096","volume":"17","author":"S Franco-Iborra","year":"2021","unstructured":"Franco-Iborra S, Plaza-Zabala A, Montpeyo M, Sebastian D, Vila M, Martinez-Vicente M (2021) Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington\u2019s disease. Autophagy 17(3):672\u2013689","journal-title":"Autophagy"},{"issue":"9","key":"13717_CR42","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awab473","volume":"145","author":"K Pircs","year":"2022","unstructured":"Pircs K, Drouin-Ouellet J, Horvath V et al (2022) Distinct subcellular autophagy impairments in induced neurons from patients with Huntington\u2019s disease. Brain 145(9):3035\u20133057","journal-title":"Brain"},{"key":"13717_CR43","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.5218.1","volume":"3","author":"RN Smith","year":"2014","unstructured":"Smith RN, Agharkar AS, Gonzales EB (2014) A review of creatine supplementation in age-related diseases: more than a supplement for athletes. F1000Res 3:222","journal-title":"F1000Res"},{"issue":"1","key":"13717_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1523\/JNEUROSCI.18-01-00156.1998","volume":"18","author":"RT Matthews","year":"1998","unstructured":"Matthews RT, Yang L, Jenkins BG et al (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington\u2019s disease. J Neurosci 18(1):156\u2013163","journal-title":"J Neurosci"},{"key":"13717_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00231","volume":"5","author":"R Wang","year":"2014","unstructured":"Wang R, Ross CA, Cai H et al (2014) Metabolic and hormonal signatures in pre-manifest and manifest Huntington\u2019s disease patients. Front Physiol 5:231","journal-title":"Front Physiol"},{"key":"13717_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2024.114864","volume":"461","author":"F Badini","year":"2024","unstructured":"Badini F, Bayrami A, Mirshekar MA, Shahraki S, Fanaei H (2024) Levothyroxine attenuates behavioral impairment and improves oxidative stress and histological alteration 3-nitropropionic acid induced experimental Huntington\u2019s disease in rats. Behav Brain Res 461:114864","journal-title":"Behav Brain Res"},{"key":"13717_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124282","author":"B Lontay","year":"2020","unstructured":"Lontay B, Kiss A, Virag L, Tar K (2020) How do post-translational modifications influence the pathomechanistic landscape of Huntington\u2019s disease? A comprehensive review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21124282","journal-title":"Int J Mol Sci"},{"issue":"1","key":"13717_CR48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/nyas.14977","volume":"1522","author":"BS Khakh","year":"2023","unstructured":"Khakh BS, Goldman SA (2023) Astrocytic contributions to Huntington\u2019s disease pathophysiology. Ann NY Acad Sci 1522(1):42\u201359","journal-title":"Ann NY Acad Sci"},{"issue":"8","key":"13717_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01319.x","volume":"13","author":"AO Robbins","year":"2006","unstructured":"Robbins AO, Ho AK, Barker RA (2006) Weight changes in Huntington\u2019s disease. Eur J Neurol 13(8):e7","journal-title":"Eur J Neurol"},{"issue":"1","key":"13717_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s10020-023-00640-7","volume":"29","author":"M Hart","year":"2023","unstructured":"Hart M, Diener C, Lunkes L et al (2023) miR-34a-5p as molecular hub of pathomechanisms in Huntington\u2019s disease. Mol Med 29(1):43","journal-title":"Mol Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13717-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13717-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13717-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T03:45:44Z","timestamp":1776656744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13717-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["13717"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13717-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest relevant to this work and that there are no additional disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"249"}}